Beyond the late breaking abstracts and plenary sessions at the European Cancer Conference being held in Vienna, Austria later this month, what other important topics can we expect to hear about?
We covered the former in the last article on Biotech Strategy Blog, today we turn our attention to the proffered (oral) sessions and what we can learn from those sessions and the expected data that is due to be presented.
There are a number of interesting topics and new data slated for presentation that are worthy of review and highlighting in a What To Watch out For (W2W4) format.
Here’s our take on the potential highlights at the meeting.
Subscribers can log in or you can sign up in the box below to learn more about the forthcoming ECCO conference.
Over the last decade we have seen some real progress with some subsets of lung cancer, particularly in EGFR mutated and ALK translocated tumours. Indeed, an incredible amount of translational work has emanated from just a few groups based in Boston, New York and Hong Kong.
Dr Jeff Engelman Source: MGH
At AACR earlier this year, Dr Jeffrey Engelman (MGH, Boston) gave a fantastic talk not just about heterogeneity, resistance mechanisms, but also on how lung cancer can transform. Included in his review was the role of biospies and how he sees those evolving.
I’ve been meaning to write up this important talk since April, but decided to wait until the key publications that were in press at the time were actually published – it was a longer wait than expected!
In general, it is our policy to write up published, rather than unpublished data, out of respect to researchers. It also makes it more useful to readers when the translational and clinical data is publicly available for those interested in reading the in-depth research articles. We also gathered commentary from other though leaders in the lung cancer space for some additional insights.
To learn more about the latest developments in the underlying complexity and clinical implications for EGFR+, T790M-positive and ALK-positive lung cancers, subscribers can log in below or you can sign up to read our comprehensive review of this topic.
The embargoed press release and abstract for Clovis’s CO–1686 (rociletinib) in advanced lung cancer patients with and without the T790M mutation, originally scheduled for Friday morning in Barcelona, was released last night. The actual presentation is slated for Friday, November 21 during the Plenary session from 11:00 to 13:00 CET.
Thus the ongoing race to market in this segment continues apace, as do the fairly robust and determined discussions on the topic. Without much further ado to read more about our quick insights and reactions to the data, you can sign up or sign in below.